Technology area: Biotechnology & Pharmaceuticals
5 pending office actions • 5 art units • 5 examiners • 0 of 5 (0%) have an AI response strategy ready • 11 patents granted in the last 365 days
Elanco US Inc. has 7 pending office actions in Biotechnology & Pharmaceuticals. Each action is assigned to a separate examiner and a separate art unit, producing a fully distributed prosecution docket. RAHMANI, NILOOFAR is the busiest examiner, with 1 pending matter.
The absence of examiner or art-unit concentration means that portfolio management should emphasize consistent disclosure positions, claim strategy, and deadline control rather than reliance on one examination pattern. Each application warrants its own assessment of the cited technology and claim issues.
Centralized tracking remains useful for identifying recurring themes across the biotechnology matters, but response drafting should remain tailored to the assigned examiner and art unit.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 2 (40%) |
| Multi-statute (no §101) | 3 (60%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| MARTINEZ, TARA L | 1 | 62.7% | +65.6% |
| STONEBRAKER, ALYSSA RAE | 1 | 58.9% | +49.4% |
| PHAN, DOAN THI-THUC | 1 | 42.8% | +47.6% |
| CURRENS, GRANT CARSON | 1 | 54.9% | +60.1% |
| NGUYEN, NAM P | 1 | 54.8% | +48.7% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18258071 | TNF ALPHA AND NGF ANTIBODIES FOR VETERINARY USE | STONEBRAKER, ALYSSA RAE | — |
| 17432725 | MICROBIAL TREATMENT | CURRENS, GRANT CARSON | — |
| 17284875 | Fc Variants with Altered Binding to Neonatal Fc Receptor (FCRN) for Veterinary Use | NGUYEN, NAM P | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 5 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17524709 | CLAY COMPOSITIONS AND METHODS FOR IMPROVING ANIMAL PERFORMANCE | PHAN, DOAN THI-THUC | 4d overdue |
| 18566294 | METHODS OF INHIBITING BOVINE MASTITIS DURING THE DRY PERIOD | MARTINEZ, TARA L | — |
| 18258071 | TNF ALPHA AND NGF ANTIBODIES FOR VETERINARY USE | STONEBRAKER, ALYSSA RAE | — |
| 17432725 | MICROBIAL TREATMENT | CURRENS, GRANT CARSON | — |
| 17284875 | Fc Variants with Altered Binding to Neonatal Fc Receptor (FCRN) for Veterinary Use | NGUYEN, NAM P | — |
| Art Unit | Apps |
|---|---|
| 1654 | 1 |
| 1642 | 1 |
| 1613 | 1 |
| 1651 | 1 |
| 1678 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18566294 | METHODS OF INHIBITING BOVINE MASTITIS DURING THE DRY PERIOD | MARTINEZ, TARA L | 1654 | §103DP | Non-Final OA | — | Pending | Dec 01, 2023 |
| 18258071 | TNF ALPHA AND NGF ANTIBODIES FOR VETERINARY USE | STONEBRAKER, ALYSSA RAE | 1642 | §102§103§112 | Non-Final OA | — | Pending | Jun 16, 2023 |
| 17524709 | CLAY COMPOSITIONS AND METHODS FOR IMPROVING ANIMAL PERFORMANCE | PHAN, DOAN THI-THUC | 1613 | §103§112DP | Final Rejection | 4d overdue | Pending | Nov 11, 2021 |
| 17432725 | MICROBIAL TREATMENT | CURRENS, GRANT CARSON | 1651 | §102§103 | Final Rejection | — | Pending | Aug 20, 2021 |
| 17284875 | Fc Variants with Altered Binding to Neonatal Fc Receptor (FCRN) for Veterinary Use | NGUYEN, NAM P | 1678 | §103§112 | Final Rejection | — | Pending | Apr 13, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialElanco US Inc. has 5 pending office actions as of October 2026, spread across 5 art units and 5 examiners.
Tara L Martinez has the most, with 1 of Elanco US Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
